Related Experiment Video
Updated: Jun 16, 2026
05:44
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
5.2K
Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma Using Non-Targeted Metabolomic Analysis
Hirofumi Sonoda1,2,3, Hideo Ogiso2, Yuichi Aoki1
1Department of Surgery, Jichi Medical University, Tochigi 329-0498, Japan.
Cancers
|February 27, 2026
Summary
Pancreatic juice analysis reveals metabolic changes in pancreatic ductal adenocarcinoma (PDAC). Specific metabolites, like citric acid, show potential as biomarkers for early PDAC detection and diagnosis.
Area of Science:
- Biochemistry
- Oncology
- Medical Diagnostics
Background:
- Liquid biopsies offer noninvasive tumor profiling via bodily fluids.
- Metabolomic analysis of bodily fluids can reflect disease pathogenesis.
- Metabolomics shows promise for clinical diagnostic applications.
Purpose of the Study:
- To investigate metabolic alterations in pancreatic ductal adenocarcinoma (PDAC).
- To analyze pancreatic juice using non-targeted metabolomics.
- To develop a preliminary diagnostic model for PDAC based on identified metabolites.
Main Methods:
- Collected pancreatic juice from PDAC and non-PDAC patients.
- Performed non-targeted metabolomic analysis using LC-QTOF-MS.
- Utilized PLS-DA for component selection and logistic regression for model construction.
Main Results:
- Identified 56 discriminative components, with 19 annotated.
- Observed one increased and 22 decreased metabolites in PDAC pancreatic juice.
- Citric acid was identified as a potential biomarker in a three-variable diagnostic model.
Conclusions:
- Pancreatic juice contains PDAC-associated metabolic changes and potential diagnostic biomarkers.
- Annotated metabolites may serve as novel markers for PDAC.
- Further research on unknown metabolites could enhance PDAC diagnosis and treatment.
